Pharmacokinetics of Intravenous and Oral Levofloxacin in Critically Ill Adults in a Medical Intensive Care Unit
Authors:
- 1 October 2002
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (10) , 1216-1225
Abstract
Study Objective. To characterize the pharmacokinetic disposition of intravenous and oral levofloxacin in critically ill adults.Design. Prospective, open‐label study.Setting. University teaching hospital.Patients. Thirty critically ill patients in a medical intensive care unit (ICU).Interventions. All patients received levofloxacin as part of their routine medical care. Pharmacokinetic evaluations were performed in 28 patients receiving intravenous levofloxacin. Ten of these patients subsequently were switched to oral levofloxacin and underwent a second pharmacokinetic evaluation during oral therapy.Measurements and Main Results. Mean ± SD levofloxacin half‐life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 ± 1.7 hours, 134 ± 35 ml/minute, and 1.2 ± 0.3 L/kg, respectively. Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration‐time curve from 0–24 hours (AUC0‐24) in patients receiving levofloxacin 500 mg intravenously were 7.5 ± 0.8 mg/L, 1.0 ± 0.5 mg/L, and 66.1 ± 15.7 mg · hour/L, respectively. Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 ± 1.1 mg/L, 0.8 ± 0.4 mg/L, and 1.3 ± 0.4 hours, respectively These values were significantly different (pmax, Cmin, half‐life, and AUC0–24 were found in critically ill patients administered multiple doses of intravenous levofloxacin compared with historical data from healthy volunteers.Conclusions. The dosage regimen of intravenous levofloxacin 500 mg once/day appears adequate for most pathogens found in critically ill patients with normal renal function. Less susceptible pathogens may require an increased daily dose for more optimal therapy. Orally administered levofloxacin appears to be well absorbed in selected ICU patients and has pharmacokinetics similar to those of intravenously administered levofloxacin.Keywords
This publication has 26 references indexed in Scilit:
- Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995Antimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract InfectionsAntimicrobial Agents and Chemotherapy, 2001
- Pharmacodynamics of LevofloxacinJAMA, 1998
- Pharmacokinetics of Drugs Used in Critically Ill AdultsClinical Pharmacokinetics, 1998
- Sequential Parenteral and Oral Ciprofloxacin Regimen versus Parenteral Therapy for Bacteremia: A Pharmacoeconomic AnalysisAnnals of Pharmacotherapy, 1996
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993
- Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibioticsThe American Journal of Medicine, 1991
- Ciprofloxacin pharmacokinetics in critically III trauma patientsThe American Journal of Medicine, 1989
- The Altered Pharmacokinetics and Pharmacodynamics of Drugs Commonly Used in Critically III PatientsClinical Pharmacokinetics, 1988
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976